Adaptive licensing - the cure for an ailing drug regulatory system?
This article was originally published in SRA
Executive Summary
The current system for evaluating and approving new drugs is ailing and a move towards an adaptive licensing process – where randomised controlled trials no longer reign supreme – would go some of the way towards solving the problems associated with it.